Accepted Manuscript CMI editorial report 2015 M. Leffad, R. Cousens, D. Raoult PII:
S1198-743X(15)00245-1
DOI:
10.1016/j.cmi.2015.02.001
Reference:
CMI 162
To appear in:
Clinical Microbiology and Infection
Received Date: 2 February 2015 Accepted Date: 2 February 2015
Please cite this article as: Leffad M, Cousens R, Raoult D, CMI editorial report 2015, Clinical Microbiology and Infection (2015), doi: 10.1016/j.cmi.2015.02.001. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
CMI editorial report 2015 1
2
M.Leffad , R. Cousens and D.Raoult
3
1) CMI Editorial Office, Marseille, France, 2) 2) Wiley-Blackwell, Oxford, UK and 3) Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, URMITE CNRS-IRD 198 UMR 6236, Faculté de Médecine, Université de la Méditerranée, Marseille, France Email: D. Raoult ([email protected])
RI PT
We thank all of our reviewers for their work in 2014.
The year 2014 is a significant change year for ESCMID’s journals, CMI and NMNI, this last journal is based in part of papers first submitted to CMI; NMNI has been accepted in PubMed and thus marks the beginning of a new
SC
breakthrough.
The ESCMID decided to change the publisher from Wiley to Elsevier and we wish to acknowledge the efforts made by
M AN U
Wiley who accompanied us during the past few years to transform this journal.
Regarding CMI the number of original articles submission has further increased, the themed issues were as diverse as possible. The publication of themed issues on time is something extremely difficult and we wish to thank Marseille team which substitute frequently to help us due to last minute defection and thanks to we can edit a themed to each number. This also represents for the publisher and for the associated editor considerable work.
TE D
Furthermore the impact of CMI in the field of infectious diseases and microbiology is increasing in a significant way, so its Impact Factor of 5.182 placing it behind Lancet Infectious Diseases, Clinical Infectious Diseases and Emerging
Diseases and AIDS.
EP
Infectious Diseases in the leading group of journals that have An impact factor greater than 5 with Journal of Infectious
Furthermore for the first time we highlight a table of the 20 most original articles cited year by year publications in infectious diseases and microbiology (Table1); this shows the role that CMI begins to play in the genesis of most cited
AC C
papers from the field.
The balance was clearly changed in recent years with the emergence of CMI among journals producing the most cited original articles in the same way as those of the Lancet Infectious Diseases has now taken the lead in terms of the number of articles most cited. We hope that this progress will continue.
We put in place with Elsevier a transfer that should enable not to fall behind to Articles and authors with great efforts of our new publisher.
1
ACCEPTED MANUSCRIPT
Table 1A .The 20 most original articles cited year by year publications in infectious diseases and microbiology these last 10 years Infectious Diseases Journal*
2004-2010
1 2 3 4 5 6 7 8 9 10
Lancet ID CID EID AIDS JID CMI JAIDS Infe control and hospita epidemiolgy Am J of infect control J.Ant. chemo
1% 35% 12% 12% 22% 0% 3% 3% 2% 3%
34% 16% 10% 9% 9% 6% 3% 2% 0% 0%
2004-2010
1 2 3 4 5 6 7 8 9 10
CID JID Cell Hostµbe ISME journal plos pathogens CMI AAC Applied & env. microbiol JCM Environm Microbiol
2011YTD**
M AN U
Journal*
TE D
Rank
SC
Microbiology
# papers cited the last 4 years 28 13 9 8 7 5 2 1 0 0
Evolution ↗ ↘ ↘ ↘ ↘ ↗ → ↘ ↘ ↘
RI PT
Rank
2011YTD**
26% 17% 7% 0% 5% 0% 6% 8% 4% 5%
25% 14% 11% 9% 8% 8% 5% 1% 1% 1%
# papers cited the last 4 years 20 11 9 7 6 6 4 1 1 1
Evolution ↘ ↘ ↗ ↗ ↗ ↗ ↘ ↘ ↘ ↘
EP
*who have had at least 1 article cited ** 16/12/2014 Sources : Thomson Reuters
AC C
Table 1B. The 40 most original articles cited year by year publications in infectious diseases and microbiology these last 10 years Microbiology Rank Journal * 2004- 2010 2011-YTD Evolution 1 CMI 0% 20% ↗ 2 Applied & environmental microbiology 30% 18% ↘ 3 Journal of Clinical Microbiology 18% 13% ↘ 4 Clinical Microbiology Reviews 0% 10% ↗ 5 Environmental Microbiology 10% 8% ↘ 6 Nature Reviews Microbiology 18% 8% ↘ 7 Molecular Microbiology 3% 0% ↘ Infectious diseases Rank 1 2 3
Journal * The lancet infectious diseases Clinical infectious diseases Emerging infectious diseases
2004- 2010 3% 58% 13%
2011-YTD 45% 35% 13%
Evolution ↗ ↘ →
2
Journal of infectious diseases 25% 5% ACCEPTED MANUSCRIPT Comparative immunology.micrbiology & infectious 3% 3% diseases Diagnostic Microbiology & infectious diseases 0% 3%
4 5 6
↘ → ↗
* who have had at least 3 article cited Sources: Scopus The various topics covered by CMI are shown in Fig.1, and show a reasonable balance between the different sections
RI PT
included in the journal. Themed sections attract attention to the priorities of infectious disease physicians–they are a real specificity of the journal. The rates of acceptance and rejection are now stable, with an acceptance rate of approximately 20% for original publications and research. Fig2. Fig.1 The evolution of CMI's thematic coverage between 2011 and 2014. Ratio 2012(%)
Ratio 2013(%)
Ratio 2014(%)
Bacteriology
34.40
36.62
36.02
34.10
Epidemiology
10.10
Infectious Diseases
21.20
Mycology
7.70
Virology
19.30
Tropical and Parasitic Diseases
7.40
M AN U
13.44
10.49
16.43
22.04
23.28
11.74
8.60
7.54
18.31
17.74
20.33
5.63
2.15
4.26
2013
34.4 0%
EP
2012
18.31 %
AC C
7.40 %
11.27
TE D
2011 19.3 0%
SC
Ratio 2011(%)
5.63 %
36.62 %
17.74
2.15 36.02
8.60
11.74 %
21.2 7.70 0% %
10.1 0%
16.43 %
11.27 %
22.04
13.44
3
ACCEPTED MANUSCRIPT
2014
Bacteriology
4.26
Epidemiology
20.33
34.10 Infectious Disease
Mycology
7.54
RI PT
Virology
10.49
Tropical and Parasitic Diseases/Parasitology
23.28
SC
Fig.2 Acceptance and rejection rates for Original Articles and Research Notes since 2008. 90
M AN U
80 70 60 50 40 30 20 0 2008
2009
1400
2011
2012
2013
1000
Decisioned
AC C
800 600 400 200
Rejection rate
2014*
EP
1200
2010
TE D
10
Acceptance rate
Accepted Rejected
0 2008
2009
2010
2011
2012
2013
2014*
* 16/12/2014
4
ACCEPTED MANUSCRIPT The Journal's Editorial Structure CMI appears monthly, and includes peer-reviewed manuscripts, reviews research notes and letters since the end of the last year. Each print and online issue includes a themed section. These are organized by a guest editor, and cover key topics. They consist of three to five invited reviews on the chosen topic, an editorial, and related cover images. Table 2 shows all of the themed sections published in 2014 and those scheduled for 2015.
Issue
Guest Editor
RI PT
Table 2. Themed sections published in CMI in 2014 and scheduled for 2015 Topic
CMI 2014 themed sections P.Brouqui
February
M. Paul
March
M.Drancourt
Emerging technology in tracking contagion Systematic review or meta-analysis? Their place in the evidence hierarchy Microbe discovery: lessons from the past
APRIL
E.Bottieau
Parasitic diseases and immunosuppression
May
D.Raoult M. Grobusch; G.Greub G.Lina
Emerging clones of bacterial epidemics
July
August
September October November December
M AN U
Bioterrorism : reality or fantasm
New epidemiology of S. aureus infection L.Kaiser; Pierre Pothier
Norovirus
G.Cornaglia & JM.Rolain
Carbapenemase in Enterobacteriaceae: a worldwide emerging concern”
D.Raoult C. Pulcini & JL. Mainardi A.Guido & E.Roilides
CMI 2015 themed sections
Fecal transplantation and infectious diseases physician
TE D
June
SC
January
Antimicrobial stewardship: an international emergency Host genetics and infections
M.Paul
February
P.Gautret
March
G.Greub &M.Paul
Bacteremia the hidden killer
APRIL
Neuraminidase inhibitors for influenza: the new evidence
June
Mical Paul S.Cutler & O.Ergonul E.Bottieau
July
T.Avsic Zupanc
New vector transmitted pathogens
August
F.Allerberger M.Poljak
Acute diarrhoea : new perspective
October
G.Antonelli
Infectious origin of cancer
November
G.Lina & G.Greub
Automation in Clinical microbiology
December
E.Tacconelli
Infection control
September
Mass Gathering
AC C
May
Infection in the elderly
EP
January
Neglected zoonases New diagnostic tools in parasitology
Human papillomaviruses
5
ACCEPTED MANUSCRIPT
Submissions
The proportion of manuscripts submitted as original articles or as research notes (separate from invited reviews and editorials) is continuously increasing. Also, these manuscripts come from a large variety of countries (Table 3); this shows that the journal is sought by many authors in various countries, even though acceptance rates are not currently equivalent for all countries. As compared with 2013, it is interesting to note that new countries, such as Morocco, have managed to publish for the first time in CMI. This clearly confirms the willingness of the journal to be open to the world, including emerging countries. It is also interesting to note that India and Republic of Korea are among the top ten
RI PT
countries submitting papers to CMI. The journal continues to make efforts to help improve papers coming from
is more consistent with the community's standards. TABLE 3. Submissions and acceptance rates by country in 2014* Number of accepted manuscripts Accept
Acceptance ratio (%)
China
178
18
10
France
141
27
Spain
136
20
Italy
114
27
69
4
Netherlands
46
12
United States
46
10
Brazil
43
3
Korea, Republic of
38
India
36
United Kingdom
34
Japan
32
Switzerland
32
Germany
29
Israel
19 15 24 6
26 22 7
TE D
Taiwan
M AN U
Number of submission
5
1
3
7
21
2
6
9
28
7
24
25
8
32
Turkey
24
1
4
Portugal
21
2
10
21
6
29
19
1
5
17
5
29
Iran, Islamic Republic of
13
0
0
Greece
11
2
18
Argentina
10
2
20
Denmark
10
5
50
Egypt
10
0
0
Austria
8
4
50
Finland
7
1
14
Poland
7
1
14
Belgium
6
1
17
Hong Kong
6
1
17
Canada
AC C
Australia
EP
2
Sweden
SC
countries with cultural and organizational difficulties, with high scientific quality, allowing them to reach a standard that
6
5
0
0
New Zealand
5
0
0
Slovenia
5
1
20
Thailand
5
4
80
Czech Republic
4
0
0
Hungary
4
0
0
Mexico
4
0
0
Norway
4
2
50
Saudi Arabia
4
1
25
Senegal
4
1
25
Singapore
4
1
25
South Africa
4
0
0
Colombia
3
0
0
Iraq
3
0
0
Romania
3
1
33
Russian Federation
3
0
0
Bosnia and Herzegovina
2
0
0
Bulgaria
2
0
0
Croatia
2
0
Cuba
2
0
Ecuador
2
1
Gambia
2
0
Iceland
2
0
Ireland
2
0
Serbia
2
0
Tunisia
2
0
0
Algeria
1
0
0
Bangladesh
1
0
0
Estonia
1
0
0
Ethiopia
1
0
0
Luxembourg
1
0
0
Madagascar
1
0
0
Morocco
1
1
100
Mozambique
1
0
0
1
0
0
1
0
0
1
0
0
1
0
0
Nigeria Oman Peru
0 0
50 0 0 0 0
TE D
EP
AC C
Nicaragua
1
0
0
Réunion
1
0
0
Slovakia
1
0
0
Viet Nam
1
0
0
1295
202
16
Philippines
SC
Malaysia
M AN U
6
RI PT
0 0MANUSCRIPT ACCEPTED
Pakistan
* 16/12/2014
7
ACCEPTED MANUSCRIPT
Citations
CMI achieved excellent results in the latest Journal Citation Reports®. Most significantly, the headline 2-year Impact Factor increased by 13% to 5.197, taking the journal above 5 for the first time. As can be seen in Figure 3, CMI’s Impact Factor has grown significantly over the last decade and is now high above the aggregate and median levels for both of its subject categories. The journal is now ranked 7 of 72 journals in Infectious Diseases, and 18 of 119 in Microbiology.
strong indicators of the journal’s prestige within the scientific community.
RI PT
CMI also achieved further growth in its Eigen Factor (up 6%) and Article Influence score (up 4%), both of which are
The most cited article published in 2013 was ‘EUCAST expert rules in antimicrobial susceptibility testing’ [1], with 52 citations to date.
SC
FIG.3. CMI’s Impact factor evolution since 2002.
M AN U
Impact Factor CMI
6
4.784
5
TE D
4.014
4
2.679 2.361
2.98
2 1.198 1
4.54 4.54
EIC- Didier Raoult
EP
2.238
4,578
3.554
3.254
3
5.197
EIC- Kevin Towner
0
AC C
EIC- Emilio Bouza
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Readership Online readership of CMI continues to grow at a very impressive rate. In 2014 total full-text downloads increased by 64% on the prior year, reaching just under 1.8 million. The two most downloaded items in 2014 were guidelines: ‘European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection’ [2], followed by ‘ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-
8
negative bacteria in hospitalized patients’ACCEPTED [3] . New publications and older papers are both strongly represented MANUSCRIPT among the most read (Table 4).
Table 4A. Most downloaded articles in 2013 Authors
Volume Issue
Lyme borreliosis: from infection to autoimmunity
Full text accesses
Ref
10
7
12321
4
M.E. Falagas & S. K. Kasiakou Mesh related infections after hernia repair surgery Multidrug resistant, extensively drug resistant and A-P. Magiorakos et al. pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance The diagnostic significance of relative bradycardia in B.A. Cunha infectious disease R. Raz Fosfomycin: an old—new antibiotic European Society of Clinical Microbiology and Infectious S. B. Debast Diseases: update of the treatment guidance document for Clostridium difficile infection D. Hill & J.P. Dubey Toxoplasma gondii: transmission, diagnosis and prevention
11
1
11750
5
18
3
9005
6
I.M. Mackay
SC
RI PT
S. K. Singh & H.J. Girschick
Article Title
P.C Woo
N/A
M AN U
Real time PCR in the microbiology laboratory Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases – Poster Sessions
6
12
7507
7
18
1
5884
8
20
s2
4615
9
8
10
4478
10
10
3
4158
11
14
10
4153
12
18
s3
4050
13
Table 4B. Most downloaded articles in 2014 YTD
Article Title
TE D
Authors
AC C
EP
European Society of Clinical Microbiology and Infectious S. B. Debast Diseases: update of the treatment guidance document for Clostridium difficile infection ESCMID guidelines for the management of the infection control measures to reduce transmission of E. Tacconelli et al. multidrug resistant Gram negative bacteria in hospitalized patients M.E. Falagas & S. K. Kasiakou Mesh related infections after hernia repair surgery Multidrug resistant, extensively drug resistant and A-P. Magiorakos et al. pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Ebola and Marburg haemorrhagic fever viruses: major E.M. Leroy et al scientific advances, but a relatively minor public health threat for Africa Antimicrobial therapy of infections with aerobic A. Von Graevenitz Gram positive rods The diagnostic significance of relative bradycardia in B.A. Cunha infectious disease R. Raz Fosfomycin: an old—new antibiotic Then and now: use of 16S rDNA gene sequencing for P.C Woo bacterial identification and discovery of novel bacteria in clinical microbiology laboratories S. K. Singh & H.J. Girschick Lyme borreliosis: from infection to autoimmunity
Volume Issue
Full text accesses
Ref
20
s2
23505
14
20
s1
20508
15
11
1
14226
16
18
3
14132
17
17
7
13035
18
7
s4
8450
19
6
12
8333
20
18
1
6934
21
14
10
6091
22
10
7
5016
23
9
ACCEPTED MANUSCRIPT
Online Publications
The number of submitted papers has not diminished; therefore, the number of quality papers that we want to publish is increasing, and, despite the increased online-only page budget, the large volume of articles makes it difficult for the time to publication in an issue to decrease. Table 5
Table 5. Year by Year Production Summary
RI PT
Average no of days from receipt at Wiley-Blackwell Year
No. of Volume(s) issues
No. of pages
No. of articles
online publication
2014
1
12
2527*
475*
222
2013
1
12
1800
316
215
2012
1
12
1804
333
2011
1
12
1912
349
175 159
2010
1
12
1798
319
101
2009
1
12
1194
200
82
2008
1
12
1200
206
58
66
2007
1
12
1244
232
80
88
2006
1
12
1266
242
83
91
218
SC
183 170 217 90
TE D
Infection Hot Topics
226
M AN U
*Clearance of article backlog at Wiley
print publication
This category of articles freely accessible continue to provided an immediate platform for the entire editorial board, and is thus closer to the discussions of the scientific community. This selection has been a real success from the time of its establishment.
EP
Future Evolution and Perspectives
The percentage of rejected articles remains very important (Table 6) but some are now redirected to NMNI, in the
AC C
future a question about the journal size might be to analyze, as well as the genesis of other associated journals. Currently in the journal editorial office we evaluate the reasons for rejection of the articles to see if this corresponds to a potential new journal. This analysis will be presented next year. The journal will continue to have a themed section per issue, as well as approximately ten original articles, on top of which Research Notes and longer articles will be available online. The journal also publishes supplementary issues (Table 7) that reflect congresses organized by the ESCMID (ECCMID), or conferences sponsored by partners; these supplements also enjoy a relatively large number of citations. The supplementary issues have been managed by the Editorial Board since 2010.
10
Table 6. Acceptance and rejection rates for Original Articles and Research Notes since 2008 ACCEPTED MANUSCRIPT Accepted
Acceptance rate (%)
Rejected
Rejection rate (%)
2008
826
240
29
586
71
2009
779
208
27
571
73
2010
995
239
24
756
76
2011
1138
214
19
924
81
2012
1177
244
21
933
79
2013
1183
236
20
947
80
2014 *
1170
202
17
968
82
* 16/12/2014
Table 7. Supplements published in CMI in 2014
Print
Sponsor
Number of paper
Ref
Articles first published online: 12 December 2013
January 2014
ESCMID
1
24
Volume 20, Issue Supplement s2 Pages 1–26
Article first published online: 20 JAN 2014
March 2014
ESCMID
26
25
ESCMID and ECMM Guidelines for the Management of Rare and Emerging Fungal Infections
Volume 20, Issue Supplement s3 Pages 1-98
Articles first published online: 9 March 2014
April 2014
ESCMID ECMM
5
26
Edited by G.Lina
European Perspective on the Use of Linezolid for the Management of Complicated Skin and Soft Tissue Infections and Nosocomial Pneumonia due to MRSA
Volume 20, Issue Supplement s4 Pages 1-36
Articles first published online: 28 February 2014
April 2014
Pfizer International Operations
3
27
Edited by Ragnar Norrby and Mario Poljak
The Impact of Vaccines on Public Health
Volume 20, Issue Supplement s5 Pages 1-117
Articles first published online January 2014 – April 2014
May 2014
ESCMID
18
28
Edited by M.Paul
Invasive Fungal Infections: Epidemiology and Treatment
Volume 20, Issue Supplement s6 Pages 1–81
Articles first published online January 2014 – April 2014
June 2014
ESCMID
81
29
Edited by G.Greub
Recommendations for the Prevention and Management of Infections in Solid Organ Transplantation (SOT): a European Perspective
Volume 20, Issue Supplement s7 Pages 1–130
Articles first published online January 2014 – April 2014
September 2014
ESCMID Study Group of Infection in Compromised Hosts (ESGICH)
130
30
Topic
Issue
Tacconelli, Evelina et al,
ESCMID Guidelines for the Management of Infection Control Measures to Reduce Volume 20, Issue Transmission of Multdrug-resistant Supplement s1 Gram-negative Bacteria in Hospitalized Pages 1-55 Patients
Bauer, Martijn; Kuijper, Edward ; van Dissel, Jaap
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
Edited by M.Paul
AC C
EP
TE D
M AN U
Authors
SC
Date of Publication Online
RI PT
Decision made
Workflow—Evolution Since 2009 The current processing time for manuscripts has continued to improve since 2009 (Table 8). In 2014, this averaged 35 days; this is broken down into 4 days for immediate rejection, and 67 days for a decision of acceptance, revision or rejection after peer-review, which, at present, appears reasonable.
11
Table 8. Evolution of the processing time for the treatment of manuscripts since 2009 ACCEPTED MANUSCRIPT Average number of days between submission and decision Immediate reject Decision after peer review (accept, revision, reject) Average processing time
2009
2010
2011
2012
2013
2014*
17
11
9
7
4
4
63
44
31
44
74
67
40
27
20
29
39
35
RI PT
*Up to 16 December 2013
Conclusion
The ambition of CMI is to reflect the academic activities of the ESCMID, and more generally of the world of infectious diseases and clinical microbiology, as well as to attract the best publications and reviews within the field. It also aims
AC C
EP
TE D
M AN U
SC
to attract attention to emerging fields or questions based on the focus provided by themed sections
12
ACCEPTED MANUSCRIPT
References 1. R. Leclercq,R. Cantón,D.F.J. Brown et al.EUCAST expert rules in antimicrobial susceptibility testing. ClinMicriobol Infect 2013; 19: 141-160. 2. Debast SB, Bauer MP, Kuijper EJ et al.European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. ClinMicrobiol Infect 2014; 20 (suppl. 2): 1-26.
RI PT
3. Tacconelli E, Cataldo MA, Dancer SJ et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014; 20 (suppl. 1):1-55. 4. S. K. Singh & H.J. Girschick et al. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004; 10:598-614.
SC
5. M.E. Falagas & S. K. Kasiakou. Mesh‐related infections after hernia repair surgery. Clin Microbiol Infect. 2005; 11:3-8.
M AN U
6. Magiorakos AP, Srinivasan A, Carey RB et al.Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81. 7. B.A. Cunha.The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ;6:633-4. 8. R. Raz. Fosfomycin: an old—new antibiotic. Clin Microbiol Infect. 2012 ;18:4-7. 9. Debast SB, Bauer MP, Kuijper EJ et al.European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 ;20 Suppl 2:1-26.
TE D
10. D. Hill, J.P. Dubey. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002 ;8:63440. 11. I.M. Mackay.Real‐time PCR in the microbiology laboratory. Clin Microbiol Infect. 2004;10:190-2012.
EP
12. Woo PC, Lau SK, Teng JL et al.Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008; 14:908-34. 13. Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases – Poster Sessions. 2012; 18, Supp 3:1–902.
AC C
14. Debast SB, Bauer MP, Kuijper EJ et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection .Clin Microbiol Infect. 2014 ;20 Supp 2:1-26.
15. Tacconelli E, Cataldo MA, Dancer SJ et al.ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug‐resistant Gram‐negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014 ;20 Supp1:1-55.
16. Falagas, M. E. and Kasiakou, S. K. Mesh‐related infections after hernia repair surgery. Clin Microbiol Infect. 2005;11: 3–8.
17. Magiorakos AP, Srinivasan A, Carey RB et al.Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 ;18:268-81.
13
ACCEPTED MANUSCRIPT 18. Leroy EM, Gonzalez JP, Baize S. et al. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-76. 19. A. Von Graevenitz.Antimicrobial therapy of infections with aerobic Gram‐positive rods. Clin Microbiol Infect. 2001;7 Supp4:43-6.
RI PT
20. B.A. Cunha.The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ;6:633-4.
21. R. Raz. Fosfomycin: an old—new antibiotic. Clin Microbiol Infect. 2012 ;18:4-7.
22. Woo PC, Lau SK, Teng JL, et al.Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008 ;14:908-34.
SC
23. S. K. Singh & H.J. Girschick .Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004 ;10:598614.
M AN U
24. E. Tacconelli, M. A. Cataldo, S. J. Dancer et al,ESCMID Guidelines for the Management of Infection Control Measures to Reduce Transmission of Multdrug-resistant Gram-negative Bacteria in Hospitalized Patients Clin Microbiol Infect 2014; 20 Supp1: 1–55.
25. Bauer, Martijn; Kuijper, Edward ; van Dissel, Jaap. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.Clin Microbiol Infect 2014; 20 Supp 2: 1–26.
TE D
26. M.Paul.ESCMID and ECMM Guidelines for the Management of Rare and Emerging Fungal Infections.Clin Microbiol Infect 2014; 20 Supp 3:1-98.
27. G.Lina.European Perspective on the Use of Linezolid for the Management of Complicated Skin and Soft Tissue Infections and Nosocomial Pneumonia due to MRSA. Clin Microbiol Infect 2014; 20 Supp 4: 1–36.
EP
28. Ragnar Norrby and Mario Poljak.The Impact of Vaccines on Public Health. Clin Microbiol Infect 2014; 20 Supp 5: 1-117.
AC C
29. M.Paul. Invasive Fungal Infections: Epidemiology and Treatment. Clin Microbiol Infect 2014; 20 Supp 6: 1–81.
30. G.Greub.Recommendations for the Prevention and Management of Infections in Solid Organ Transplantation (SOT): a European Perspective. Clin Microbiol Infect 2014; 20 Supp 7: 1–130.
14
S1198-743X(15)00245-1
DOI:
10.1016/j.cmi.2015.02.001
Reference:
CMI 162
To appear in:
Clinical Microbiology and Infection
Received Date: 2 February 2015 Accepted Date: 2 February 2015
Please cite this article as: Leffad M, Cousens R, Raoult D, CMI editorial report 2015, Clinical Microbiology and Infection (2015), doi: 10.1016/j.cmi.2015.02.001. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
CMI editorial report 2015 1
2
M.Leffad , R. Cousens and D.Raoult
3
1) CMI Editorial Office, Marseille, France, 2) 2) Wiley-Blackwell, Oxford, UK and 3) Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, URMITE CNRS-IRD 198 UMR 6236, Faculté de Médecine, Université de la Méditerranée, Marseille, France Email: D. Raoult ([email protected])
RI PT
We thank all of our reviewers for their work in 2014.
The year 2014 is a significant change year for ESCMID’s journals, CMI and NMNI, this last journal is based in part of papers first submitted to CMI; NMNI has been accepted in PubMed and thus marks the beginning of a new
SC
breakthrough.
The ESCMID decided to change the publisher from Wiley to Elsevier and we wish to acknowledge the efforts made by
M AN U
Wiley who accompanied us during the past few years to transform this journal.
Regarding CMI the number of original articles submission has further increased, the themed issues were as diverse as possible. The publication of themed issues on time is something extremely difficult and we wish to thank Marseille team which substitute frequently to help us due to last minute defection and thanks to we can edit a themed to each number. This also represents for the publisher and for the associated editor considerable work.
TE D
Furthermore the impact of CMI in the field of infectious diseases and microbiology is increasing in a significant way, so its Impact Factor of 5.182 placing it behind Lancet Infectious Diseases, Clinical Infectious Diseases and Emerging
Diseases and AIDS.
EP
Infectious Diseases in the leading group of journals that have An impact factor greater than 5 with Journal of Infectious
Furthermore for the first time we highlight a table of the 20 most original articles cited year by year publications in infectious diseases and microbiology (Table1); this shows the role that CMI begins to play in the genesis of most cited
AC C
papers from the field.
The balance was clearly changed in recent years with the emergence of CMI among journals producing the most cited original articles in the same way as those of the Lancet Infectious Diseases has now taken the lead in terms of the number of articles most cited. We hope that this progress will continue.
We put in place with Elsevier a transfer that should enable not to fall behind to Articles and authors with great efforts of our new publisher.
1
ACCEPTED MANUSCRIPT
Table 1A .The 20 most original articles cited year by year publications in infectious diseases and microbiology these last 10 years Infectious Diseases Journal*
2004-2010
1 2 3 4 5 6 7 8 9 10
Lancet ID CID EID AIDS JID CMI JAIDS Infe control and hospita epidemiolgy Am J of infect control J.Ant. chemo
1% 35% 12% 12% 22% 0% 3% 3% 2% 3%
34% 16% 10% 9% 9% 6% 3% 2% 0% 0%
2004-2010
1 2 3 4 5 6 7 8 9 10
CID JID Cell Hostµbe ISME journal plos pathogens CMI AAC Applied & env. microbiol JCM Environm Microbiol
2011YTD**
M AN U
Journal*
TE D
Rank
SC
Microbiology
# papers cited the last 4 years 28 13 9 8 7 5 2 1 0 0
Evolution ↗ ↘ ↘ ↘ ↘ ↗ → ↘ ↘ ↘
RI PT
Rank
2011YTD**
26% 17% 7% 0% 5% 0% 6% 8% 4% 5%
25% 14% 11% 9% 8% 8% 5% 1% 1% 1%
# papers cited the last 4 years 20 11 9 7 6 6 4 1 1 1
Evolution ↘ ↘ ↗ ↗ ↗ ↗ ↘ ↘ ↘ ↘
EP
*who have had at least 1 article cited ** 16/12/2014 Sources : Thomson Reuters
AC C
Table 1B. The 40 most original articles cited year by year publications in infectious diseases and microbiology these last 10 years Microbiology Rank Journal * 2004- 2010 2011-YTD Evolution 1 CMI 0% 20% ↗ 2 Applied & environmental microbiology 30% 18% ↘ 3 Journal of Clinical Microbiology 18% 13% ↘ 4 Clinical Microbiology Reviews 0% 10% ↗ 5 Environmental Microbiology 10% 8% ↘ 6 Nature Reviews Microbiology 18% 8% ↘ 7 Molecular Microbiology 3% 0% ↘ Infectious diseases Rank 1 2 3
Journal * The lancet infectious diseases Clinical infectious diseases Emerging infectious diseases
2004- 2010 3% 58% 13%
2011-YTD 45% 35% 13%
Evolution ↗ ↘ →
2
Journal of infectious diseases 25% 5% ACCEPTED MANUSCRIPT Comparative immunology.micrbiology & infectious 3% 3% diseases Diagnostic Microbiology & infectious diseases 0% 3%
4 5 6
↘ → ↗
* who have had at least 3 article cited Sources: Scopus The various topics covered by CMI are shown in Fig.1, and show a reasonable balance between the different sections
RI PT
included in the journal. Themed sections attract attention to the priorities of infectious disease physicians–they are a real specificity of the journal. The rates of acceptance and rejection are now stable, with an acceptance rate of approximately 20% for original publications and research. Fig2. Fig.1 The evolution of CMI's thematic coverage between 2011 and 2014. Ratio 2012(%)
Ratio 2013(%)
Ratio 2014(%)
Bacteriology
34.40
36.62
36.02
34.10
Epidemiology
10.10
Infectious Diseases
21.20
Mycology
7.70
Virology
19.30
Tropical and Parasitic Diseases
7.40
M AN U
13.44
10.49
16.43
22.04
23.28
11.74
8.60
7.54
18.31
17.74
20.33
5.63
2.15
4.26
2013
34.4 0%
EP
2012
18.31 %
AC C
7.40 %
11.27
TE D
2011 19.3 0%
SC
Ratio 2011(%)
5.63 %
36.62 %
17.74
2.15 36.02
8.60
11.74 %
21.2 7.70 0% %
10.1 0%
16.43 %
11.27 %
22.04
13.44
3
ACCEPTED MANUSCRIPT
2014
Bacteriology
4.26
Epidemiology
20.33
34.10 Infectious Disease
Mycology
7.54
RI PT
Virology
10.49
Tropical and Parasitic Diseases/Parasitology
23.28
SC
Fig.2 Acceptance and rejection rates for Original Articles and Research Notes since 2008. 90
M AN U
80 70 60 50 40 30 20 0 2008
2009
1400
2011
2012
2013
1000
Decisioned
AC C
800 600 400 200
Rejection rate
2014*
EP
1200
2010
TE D
10
Acceptance rate
Accepted Rejected
0 2008
2009
2010
2011
2012
2013
2014*
* 16/12/2014
4
ACCEPTED MANUSCRIPT The Journal's Editorial Structure CMI appears monthly, and includes peer-reviewed manuscripts, reviews research notes and letters since the end of the last year. Each print and online issue includes a themed section. These are organized by a guest editor, and cover key topics. They consist of three to five invited reviews on the chosen topic, an editorial, and related cover images. Table 2 shows all of the themed sections published in 2014 and those scheduled for 2015.
Issue
Guest Editor
RI PT
Table 2. Themed sections published in CMI in 2014 and scheduled for 2015 Topic
CMI 2014 themed sections P.Brouqui
February
M. Paul
March
M.Drancourt
Emerging technology in tracking contagion Systematic review or meta-analysis? Their place in the evidence hierarchy Microbe discovery: lessons from the past
APRIL
E.Bottieau
Parasitic diseases and immunosuppression
May
D.Raoult M. Grobusch; G.Greub G.Lina
Emerging clones of bacterial epidemics
July
August
September October November December
M AN U
Bioterrorism : reality or fantasm
New epidemiology of S. aureus infection L.Kaiser; Pierre Pothier
Norovirus
G.Cornaglia & JM.Rolain
Carbapenemase in Enterobacteriaceae: a worldwide emerging concern”
D.Raoult C. Pulcini & JL. Mainardi A.Guido & E.Roilides
CMI 2015 themed sections
Fecal transplantation and infectious diseases physician
TE D
June
SC
January
Antimicrobial stewardship: an international emergency Host genetics and infections
M.Paul
February
P.Gautret
March
G.Greub &M.Paul
Bacteremia the hidden killer
APRIL
Neuraminidase inhibitors for influenza: the new evidence
June
Mical Paul S.Cutler & O.Ergonul E.Bottieau
July
T.Avsic Zupanc
New vector transmitted pathogens
August
F.Allerberger M.Poljak
Acute diarrhoea : new perspective
October
G.Antonelli
Infectious origin of cancer
November
G.Lina & G.Greub
Automation in Clinical microbiology
December
E.Tacconelli
Infection control
September
Mass Gathering
AC C
May
Infection in the elderly
EP
January
Neglected zoonases New diagnostic tools in parasitology
Human papillomaviruses
5
ACCEPTED MANUSCRIPT
Submissions
The proportion of manuscripts submitted as original articles or as research notes (separate from invited reviews and editorials) is continuously increasing. Also, these manuscripts come from a large variety of countries (Table 3); this shows that the journal is sought by many authors in various countries, even though acceptance rates are not currently equivalent for all countries. As compared with 2013, it is interesting to note that new countries, such as Morocco, have managed to publish for the first time in CMI. This clearly confirms the willingness of the journal to be open to the world, including emerging countries. It is also interesting to note that India and Republic of Korea are among the top ten
RI PT
countries submitting papers to CMI. The journal continues to make efforts to help improve papers coming from
is more consistent with the community's standards. TABLE 3. Submissions and acceptance rates by country in 2014* Number of accepted manuscripts Accept
Acceptance ratio (%)
China
178
18
10
France
141
27
Spain
136
20
Italy
114
27
69
4
Netherlands
46
12
United States
46
10
Brazil
43
3
Korea, Republic of
38
India
36
United Kingdom
34
Japan
32
Switzerland
32
Germany
29
Israel
19 15 24 6
26 22 7
TE D
Taiwan
M AN U
Number of submission
5
1
3
7
21
2
6
9
28
7
24
25
8
32
Turkey
24
1
4
Portugal
21
2
10
21
6
29
19
1
5
17
5
29
Iran, Islamic Republic of
13
0
0
Greece
11
2
18
Argentina
10
2
20
Denmark
10
5
50
Egypt
10
0
0
Austria
8
4
50
Finland
7
1
14
Poland
7
1
14
Belgium
6
1
17
Hong Kong
6
1
17
Canada
AC C
Australia
EP
2
Sweden
SC
countries with cultural and organizational difficulties, with high scientific quality, allowing them to reach a standard that
6
5
0
0
New Zealand
5
0
0
Slovenia
5
1
20
Thailand
5
4
80
Czech Republic
4
0
0
Hungary
4
0
0
Mexico
4
0
0
Norway
4
2
50
Saudi Arabia
4
1
25
Senegal
4
1
25
Singapore
4
1
25
South Africa
4
0
0
Colombia
3
0
0
Iraq
3
0
0
Romania
3
1
33
Russian Federation
3
0
0
Bosnia and Herzegovina
2
0
0
Bulgaria
2
0
0
Croatia
2
0
Cuba
2
0
Ecuador
2
1
Gambia
2
0
Iceland
2
0
Ireland
2
0
Serbia
2
0
Tunisia
2
0
0
Algeria
1
0
0
Bangladesh
1
0
0
Estonia
1
0
0
Ethiopia
1
0
0
Luxembourg
1
0
0
Madagascar
1
0
0
Morocco
1
1
100
Mozambique
1
0
0
1
0
0
1
0
0
1
0
0
1
0
0
Nigeria Oman Peru
0 0
50 0 0 0 0
TE D
EP
AC C
Nicaragua
1
0
0
Réunion
1
0
0
Slovakia
1
0
0
Viet Nam
1
0
0
1295
202
16
Philippines
SC
Malaysia
M AN U
6
RI PT
0 0MANUSCRIPT ACCEPTED
Pakistan
* 16/12/2014
7
ACCEPTED MANUSCRIPT
Citations
CMI achieved excellent results in the latest Journal Citation Reports®. Most significantly, the headline 2-year Impact Factor increased by 13% to 5.197, taking the journal above 5 for the first time. As can be seen in Figure 3, CMI’s Impact Factor has grown significantly over the last decade and is now high above the aggregate and median levels for both of its subject categories. The journal is now ranked 7 of 72 journals in Infectious Diseases, and 18 of 119 in Microbiology.
strong indicators of the journal’s prestige within the scientific community.
RI PT
CMI also achieved further growth in its Eigen Factor (up 6%) and Article Influence score (up 4%), both of which are
The most cited article published in 2013 was ‘EUCAST expert rules in antimicrobial susceptibility testing’ [1], with 52 citations to date.
SC
FIG.3. CMI’s Impact factor evolution since 2002.
M AN U
Impact Factor CMI
6
4.784
5
TE D
4.014
4
2.679 2.361
2.98
2 1.198 1
4.54 4.54
EIC- Didier Raoult
EP
2.238
4,578
3.554
3.254
3
5.197
EIC- Kevin Towner
0
AC C
EIC- Emilio Bouza
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Readership Online readership of CMI continues to grow at a very impressive rate. In 2014 total full-text downloads increased by 64% on the prior year, reaching just under 1.8 million. The two most downloaded items in 2014 were guidelines: ‘European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection’ [2], followed by ‘ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-
8
negative bacteria in hospitalized patients’ACCEPTED [3] . New publications and older papers are both strongly represented MANUSCRIPT among the most read (Table 4).
Table 4A. Most downloaded articles in 2013 Authors
Volume Issue
Lyme borreliosis: from infection to autoimmunity
Full text accesses
Ref
10
7
12321
4
M.E. Falagas & S. K. Kasiakou Mesh related infections after hernia repair surgery Multidrug resistant, extensively drug resistant and A-P. Magiorakos et al. pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance The diagnostic significance of relative bradycardia in B.A. Cunha infectious disease R. Raz Fosfomycin: an old—new antibiotic European Society of Clinical Microbiology and Infectious S. B. Debast Diseases: update of the treatment guidance document for Clostridium difficile infection D. Hill & J.P. Dubey Toxoplasma gondii: transmission, diagnosis and prevention
11
1
11750
5
18
3
9005
6
I.M. Mackay
SC
RI PT
S. K. Singh & H.J. Girschick
Article Title
P.C Woo
N/A
M AN U
Real time PCR in the microbiology laboratory Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases – Poster Sessions
6
12
7507
7
18
1
5884
8
20
s2
4615
9
8
10
4478
10
10
3
4158
11
14
10
4153
12
18
s3
4050
13
Table 4B. Most downloaded articles in 2014 YTD
Article Title
TE D
Authors
AC C
EP
European Society of Clinical Microbiology and Infectious S. B. Debast Diseases: update of the treatment guidance document for Clostridium difficile infection ESCMID guidelines for the management of the infection control measures to reduce transmission of E. Tacconelli et al. multidrug resistant Gram negative bacteria in hospitalized patients M.E. Falagas & S. K. Kasiakou Mesh related infections after hernia repair surgery Multidrug resistant, extensively drug resistant and A-P. Magiorakos et al. pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Ebola and Marburg haemorrhagic fever viruses: major E.M. Leroy et al scientific advances, but a relatively minor public health threat for Africa Antimicrobial therapy of infections with aerobic A. Von Graevenitz Gram positive rods The diagnostic significance of relative bradycardia in B.A. Cunha infectious disease R. Raz Fosfomycin: an old—new antibiotic Then and now: use of 16S rDNA gene sequencing for P.C Woo bacterial identification and discovery of novel bacteria in clinical microbiology laboratories S. K. Singh & H.J. Girschick Lyme borreliosis: from infection to autoimmunity
Volume Issue
Full text accesses
Ref
20
s2
23505
14
20
s1
20508
15
11
1
14226
16
18
3
14132
17
17
7
13035
18
7
s4
8450
19
6
12
8333
20
18
1
6934
21
14
10
6091
22
10
7
5016
23
9
ACCEPTED MANUSCRIPT
Online Publications
The number of submitted papers has not diminished; therefore, the number of quality papers that we want to publish is increasing, and, despite the increased online-only page budget, the large volume of articles makes it difficult for the time to publication in an issue to decrease. Table 5
Table 5. Year by Year Production Summary
RI PT
Average no of days from receipt at Wiley-Blackwell Year
No. of Volume(s) issues
No. of pages
No. of articles
online publication
2014
1
12
2527*
475*
222
2013
1
12
1800
316
215
2012
1
12
1804
333
2011
1
12
1912
349
175 159
2010
1
12
1798
319
101
2009
1
12
1194
200
82
2008
1
12
1200
206
58
66
2007
1
12
1244
232
80
88
2006
1
12
1266
242
83
91
218
SC
183 170 217 90
TE D
Infection Hot Topics
226
M AN U
*Clearance of article backlog at Wiley
print publication
This category of articles freely accessible continue to provided an immediate platform for the entire editorial board, and is thus closer to the discussions of the scientific community. This selection has been a real success from the time of its establishment.
EP
Future Evolution and Perspectives
The percentage of rejected articles remains very important (Table 6) but some are now redirected to NMNI, in the
AC C
future a question about the journal size might be to analyze, as well as the genesis of other associated journals. Currently in the journal editorial office we evaluate the reasons for rejection of the articles to see if this corresponds to a potential new journal. This analysis will be presented next year. The journal will continue to have a themed section per issue, as well as approximately ten original articles, on top of which Research Notes and longer articles will be available online. The journal also publishes supplementary issues (Table 7) that reflect congresses organized by the ESCMID (ECCMID), or conferences sponsored by partners; these supplements also enjoy a relatively large number of citations. The supplementary issues have been managed by the Editorial Board since 2010.
10
Table 6. Acceptance and rejection rates for Original Articles and Research Notes since 2008 ACCEPTED MANUSCRIPT Accepted
Acceptance rate (%)
Rejected
Rejection rate (%)
2008
826
240
29
586
71
2009
779
208
27
571
73
2010
995
239
24
756
76
2011
1138
214
19
924
81
2012
1177
244
21
933
79
2013
1183
236
20
947
80
2014 *
1170
202
17
968
82
* 16/12/2014
Table 7. Supplements published in CMI in 2014
Sponsor
Number of paper
Ref
Articles first published online: 12 December 2013
January 2014
ESCMID
1
24
Volume 20, Issue Supplement s2 Pages 1–26
Article first published online: 20 JAN 2014
March 2014
ESCMID
26
25
ESCMID and ECMM Guidelines for the Management of Rare and Emerging Fungal Infections
Volume 20, Issue Supplement s3 Pages 1-98
Articles first published online: 9 March 2014
April 2014
ESCMID ECMM
5
26
Edited by G.Lina
European Perspective on the Use of Linezolid for the Management of Complicated Skin and Soft Tissue Infections and Nosocomial Pneumonia due to MRSA
Volume 20, Issue Supplement s4 Pages 1-36
Articles first published online: 28 February 2014
April 2014
Pfizer International Operations
3
27
Edited by Ragnar Norrby and Mario Poljak
The Impact of Vaccines on Public Health
Volume 20, Issue Supplement s5 Pages 1-117
Articles first published online January 2014 – April 2014
May 2014
ESCMID
18
28
Edited by M.Paul
Invasive Fungal Infections: Epidemiology and Treatment
Volume 20, Issue Supplement s6 Pages 1–81
Articles first published online January 2014 – April 2014
June 2014
ESCMID
81
29
Edited by G.Greub
Recommendations for the Prevention and Management of Infections in Solid Organ Transplantation (SOT): a European Perspective
Volume 20, Issue Supplement s7 Pages 1–130
Articles first published online January 2014 – April 2014
September 2014
ESCMID Study Group of Infection in Compromised Hosts (ESGICH)
130
30
Topic
Issue
Tacconelli, Evelina et al,
ESCMID Guidelines for the Management of Infection Control Measures to Reduce Volume 20, Issue Transmission of Multdrug-resistant Supplement s1 Gram-negative Bacteria in Hospitalized Pages 1-55 Patients
Bauer, Martijn; Kuijper, Edward ; van Dissel, Jaap
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
Edited by M.Paul
AC C
EP
TE D
M AN U
Authors
SC
Date of Publication Online
RI PT
Decision made
Workflow—Evolution Since 2009 The current processing time for manuscripts has continued to improve since 2009 (Table 8). In 2014, this averaged 35 days; this is broken down into 4 days for immediate rejection, and 67 days for a decision of acceptance, revision or rejection after peer-review, which, at present, appears reasonable.
11
Table 8. Evolution of the processing time for the treatment of manuscripts since 2009 ACCEPTED MANUSCRIPT Average number of days between submission and decision Immediate reject Decision after peer review (accept, revision, reject) Average processing time
2009
2010
2011
2012
2013
2014*
17
11
9
7
4
4
63
44
31
44
74
67
40
27
20
29
39
35
RI PT
*Up to 16 December 2013
Conclusion
The ambition of CMI is to reflect the academic activities of the ESCMID, and more generally of the world of infectious diseases and clinical microbiology, as well as to attract the best publications and reviews within the field. It also aims
AC C
EP
TE D
M AN U
SC
to attract attention to emerging fields or questions based on the focus provided by themed sections
12
ACCEPTED MANUSCRIPT
References 1. R. Leclercq,R. Cantón,D.F.J. Brown et al.EUCAST expert rules in antimicrobial susceptibility testing. ClinMicriobol Infect 2013; 19: 141-160. 2. Debast SB, Bauer MP, Kuijper EJ et al.European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. ClinMicrobiol Infect 2014; 20 (suppl. 2): 1-26.
RI PT
3. Tacconelli E, Cataldo MA, Dancer SJ et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014; 20 (suppl. 1):1-55. 4. S. K. Singh & H.J. Girschick et al. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004; 10:598-614.
SC
5. M.E. Falagas & S. K. Kasiakou. Mesh‐related infections after hernia repair surgery. Clin Microbiol Infect. 2005; 11:3-8.
M AN U
6. Magiorakos AP, Srinivasan A, Carey RB et al.Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81. 7. B.A. Cunha.The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ;6:633-4. 8. R. Raz. Fosfomycin: an old—new antibiotic. Clin Microbiol Infect. 2012 ;18:4-7. 9. Debast SB, Bauer MP, Kuijper EJ et al.European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 ;20 Suppl 2:1-26.
TE D
10. D. Hill, J.P. Dubey. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002 ;8:63440. 11. I.M. Mackay.Real‐time PCR in the microbiology laboratory. Clin Microbiol Infect. 2004;10:190-2012.
EP
12. Woo PC, Lau SK, Teng JL et al.Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008; 14:908-34. 13. Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases – Poster Sessions. 2012; 18, Supp 3:1–902.
AC C
14. Debast SB, Bauer MP, Kuijper EJ et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection .Clin Microbiol Infect. 2014 ;20 Supp 2:1-26.
15. Tacconelli E, Cataldo MA, Dancer SJ et al.ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug‐resistant Gram‐negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014 ;20 Supp1:1-55.
16. Falagas, M. E. and Kasiakou, S. K. Mesh‐related infections after hernia repair surgery. Clin Microbiol Infect. 2005;11: 3–8.
17. Magiorakos AP, Srinivasan A, Carey RB et al.Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 ;18:268-81.
13
ACCEPTED MANUSCRIPT 18. Leroy EM, Gonzalez JP, Baize S. et al. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-76. 19. A. Von Graevenitz.Antimicrobial therapy of infections with aerobic Gram‐positive rods. Clin Microbiol Infect. 2001;7 Supp4:43-6.
RI PT
20. B.A. Cunha.The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000 ;6:633-4.
21. R. Raz. Fosfomycin: an old—new antibiotic. Clin Microbiol Infect. 2012 ;18:4-7.
22. Woo PC, Lau SK, Teng JL, et al.Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect. 2008 ;14:908-34.
SC
23. S. K. Singh & H.J. Girschick .Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004 ;10:598614.
M AN U
24. E. Tacconelli, M. A. Cataldo, S. J. Dancer et al,ESCMID Guidelines for the Management of Infection Control Measures to Reduce Transmission of Multdrug-resistant Gram-negative Bacteria in Hospitalized Patients Clin Microbiol Infect 2014; 20 Supp1: 1–55.
25. Bauer, Martijn; Kuijper, Edward ; van Dissel, Jaap. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.Clin Microbiol Infect 2014; 20 Supp 2: 1–26.
TE D
26. M.Paul.ESCMID and ECMM Guidelines for the Management of Rare and Emerging Fungal Infections.Clin Microbiol Infect 2014; 20 Supp 3:1-98.
27. G.Lina.European Perspective on the Use of Linezolid for the Management of Complicated Skin and Soft Tissue Infections and Nosocomial Pneumonia due to MRSA. Clin Microbiol Infect 2014; 20 Supp 4: 1–36.
EP
28. Ragnar Norrby and Mario Poljak.The Impact of Vaccines on Public Health. Clin Microbiol Infect 2014; 20 Supp 5: 1-117.
AC C
29. M.Paul. Invasive Fungal Infections: Epidemiology and Treatment. Clin Microbiol Infect 2014; 20 Supp 6: 1–81.
30. G.Greub.Recommendations for the Prevention and Management of Infections in Solid Organ Transplantation (SOT): a European Perspective. Clin Microbiol Infect 2014; 20 Supp 7: 1–130.
14
